WellRX, the parent company of preventative healthcare brands ReviveRX and Ways2Well, has acquired Bioreach, an advanced bloodwork and genetics laboratory. This acquisition enhances WellRX's ability to offer advanced blood testing services, making diagnostics more efficient and enabling the company to provide innovative health tests across its ecosystem, which includes partner telehealth clinics, weight-loss programmes, testosterone therapies, and regenerative medicine services.

Bioreach’s cutting-edge capabilities will help WellRX speed up blood test results and provide deeper insights into patient health. By integrating Bioreach’s services, WellRX aims to reduce costs, achieve seamless integration, and deliver proactive healthcare.

This move aligns with WellRX’s focus on healthspan optimisation, with the goal of offering greater innovation and value to patients, clinicians, and providers.

The addition of Bioreach will improve patient outcomes by supporting clinics with data-driven health solutions. Telehealth providers using ReviveRX for prescription services will benefit from integrated bloodwork, offering more comprehensive care to their patients.

The acquisition also expands the range of tests available through Ways2Well, WellRX’s telehealth clinic focused on preventative care and functional medicine, which serves over 50,000 patients nationwide.

Bioreach’s advanced technology enables faster testing, with results available in just one day instead of the traditional five to seven business days.

This efficiency improvement will benefit both patients and healthcare providers. With this acquisition, WellRX, ReviveRX, and Ways2Well are set to continue developing cutting-edge tests, driving progress in early disease detection and diagnosis.




Source: businesswire.com

Report Abuse